Alphamab Oncology (HKG:9966) presented the results of a phase 1/2 study of its JSKN033 treatment during a cancer immunotherapy summit in Houston, according to a Sunday filing with the Hong Kong Exchange.
JSKN033 is indicated for HER2-expressing advanced or metastatic solid tumors.
The study showed favorable anti-tumor activity while exhibiting safety, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.